ADVERTISEMENT



Google       

Home -> Law Blog Directory -> Patent Law Blogs -> Patent Baristas

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Patent Law

: Patent Baristas

Is the USPTO Striking Back With Double Patenting Rejections?

By Stephen Albainy-Jenei

ADVERTISEMENTS

Greg Aharonian at Internet Patent News Service posted note about a possible increase in double-patenting rejections as the U.S. Patent Office. In a complaint he received, a reader questions whether this is an orchestrated implementation of “directives to frustrate patent applicants to achieve their misguided purpose.”

As an example, the reader noted that the Patent Office seems to be (undeservedly) dishing out more statutory double patenting rejections. Although the example dealt with claims directed to computer readable storage media and accompanying systems and methods, this can also be a problem in the bio/pharma where drug companies are constantly trying to file patent applications on continued changes and improvements in order to capture or retain market share.

Basically, the law provides that an applicant may only obtain a single patent for an invention. 35 USC 101 provides:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Thus, a statutory double patenting rejection comes up when the applicant tries to claim the exact same invention. The purpose, of course, is to prevent a patentee from receiving multiple patents for the same invention and thus gaining an illegal extension of patent term. Therefore, a pharmaceutical company can only be able to prevent generic entry for a period of 20 years from the filing date of the application (albeit with certain extensions available).

One quick test of whether or not there’s a problem is to ask:

  1. Is there an embodiment that falls within the scope of one claim, but not the other?
  2. Could one claim be literally infringed without literally infringing the other claim?

Since bio & pharma patents seem to be under seige, I’m curious if others have experienced an uptick in statutory-type double patenting rejections?

Let us know.

more at twiigs.com…

Full post as published by Patent Baristas on April 23, 2008 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0126 secs (new cache)